In the last decade the inhibition of the enzyme 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) emerged as a promising new strategy to treat diabetes and several metabolic syndrome phenotypes. Using a molecular modeling approach and classical bioisosteric studies, we discovered a new class of 11β-HSD1 inhibitors bearing an arylsulfonylpiperazine scaffold. Optimization of the initial lead resulted in compound 11 that selectively inhibits 11β-HSD1 (IC50=0.7 μM).
Keywords: 11β-Hydroxysteroid dehydrogenase; 2-Benzazolylpiperazine; Metabolic diseases; Molecular modeling; Structure–activity relationships (SAR).
Copyright © 2013 Elsevier Ltd. All rights reserved.